LLY stock forecast
Our latest prediction for Eli Lilly & Co.'s stock price was made on the Jan. 8, 2020 when the stock price was at 133.71$.
In the short term (2weeks), LLY's stock price should underperform the market by -3.33%. During that period the price should oscillate between -4.25% and +2.72%.
In the medium term (3months), LLY's stock price should underperform the market by -1.76%. During that period the price should oscillate between -9.99% and +8.91%.Get email alerts
About Eli Lilly & Co.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
At the moment the company generates 24906M USD in revenues.
On its last earning announcement, the company reported a profit of 8.34$ per share.
The book value per share is 10.76$
Three months stock forecastJan. 8, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|